A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
A Phase I Study of YY-20394 Given Orally to Patients With Relapsed or Refractory B Cell Hematologic Malignancies
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
A PHASE1 clinical study on B-cell Chronic Lymphocytic Leukemia and B-cell Lymphoma Recurrent, this trial is ongoing. The trial is conducted by Shanghai YingLi Pharmaceutical Co. Ltd. and has accumulated 5 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2019 — Jan 2021 [monthly]
Recruiting PHASE1
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE1
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai YingLi Pharmaceutical Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .